Plant Signaling Pathways Decoded
On Aug. 28, 2024, the University of Würzburg announced research using newly generated “optogenetic” tobacco plants to investigated…
-
-
Pfizer and BioNTech Received U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
On Aug. 22, 2024, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had approved…
-
BioNTech sued by UPenn over COVID-19 vaccine patent royalties
On Aug. 6, 2024, the University of Pennsylvania announced it had sued German biotechnology firm BioNTech n Pennsylvania…
-
Biotechnology | Disease | HIV | Therapeutics | WHO
A seventh case of HIV cure reported
On Jul. 25, 2024, the World Health Organization (WHO) announced during the 25th International AIDS Conference, being held…
-
Disease | Genomics | Neurology | Veterinary
Paralyzed mountain lion found in Colorado first case of “staggering disease” in North America
On Jul. 15, 2024, Colorado Parks and Wildlife officials announced the first finding of ‘rustrela virus’ in a…
-
BioNTech and CEPI Expanded Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
On May 29, 2024, BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they were expanding their…
-
Psittacosis reported in European region
On Mar. 5, 2024, the World Health Organization (WHO) announced that in February 2024, Austria, Denmark, Germany, Sweden…
-
Pfizer and BioNTech received Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
On Sept. 28, 2023, Pfizer and BioNTech that Health Canada had authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19…
-
Pfizer and BioNTech received U.S. FDA approval for 2023-2024 COVID-19 vaccine
On Sept. 11, 2023, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…
-
COVID-19 | FDA | Infectious Disease | Vaccine
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
On Aug. 30, 2023, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Genome analysis of revived 46,000-year-old roundworm from Siberian permafrost revealed a novel species
On Jul. 28, 2023, researchers from the Institute of Zoology at the University of Cologne, the Max Planck…
-
U.S. FDA approved new class of medicines to treat pediatric type 2 diabetes
On Jun. 20, 2023, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s Jardiance (empagliflozin) and Synjardy…
-
Boehringer Ingelheim inaugurated largest European development centre for biotechnology
On Apr. 24, 2023, Boehringer Ingelheim inaugurated its state-of-the-art Biologicals Development Center in Biberach an der Riss, Germany….
-
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, National Institutes of Health (NIH) scientists announced that the magnitude and quality of a…
-
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Biotechnology | COVID-19 | Medicine | Vaccine
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
-
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
-
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Global leaders committed US$ 2.6 billion at World Health Summit to end polio
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
-
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
-
Biotechnology | CDC | COVID-19 | FDA | Infectious Disease | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
-
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5-adapted bivalent vaccine Booster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech announced updated COVID-19 vaccine data supporting efficacy in children 6 months through 4 years of age
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
-
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
On Aug. 22, 2022, Pfizer and BioNTech announced they had completed a submission to the U.S. Food and…
-
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
-
Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
